Akouos
Akouos is a biotechnology company specializing in the development of gene therapies aimed at treating sensorineural hearing loss, utilizing its Ancestral AAV Technology platform.
Company Overview
Akouos is a biotech company focused on developing gene therapies aimed at restoring, improving, and preserving high-acuity physiologic hearing. Their efforts primarily target individuals suffering from disabling hearing loss using advanced genetic approaches. The company's mission revolves around innovating solutions to combat sensorineural hearing loss, a prevalent cause of hearing impairment.
Gene Therapy for Hearing Loss
Akouos develops targeted adeno-associated viral (AAV) vector-based gene therapies to address sensorineural hearing loss. This condition is often caused by damage or mutations in specific genes related to hearing. Akouos is pioneering the use of gene therapy to introduce or correct these genes, potentially restoring hearing function in affected individuals.
Clinical Trials and Research
Akouos has initiated a Phase 1/2 clinical trial of AK-OTOF, a gene therapy specifically designed to treat sensorineural hearing loss caused by mutations in the otoferlin gene. This clinical trial represents a significant step in translating their genetic research into potential treatments that could offer relief for those with genetic hearing impairments.
Ancestral AAV Technology
The company leverages its proprietary Ancestral AAV (AAVAnc) Technology platform to develop therapies for disorders related to the inner ear, hearing, and balance. This innovative platform enhances the delivery and efficacy of gene therapies by utilizing optimized viral vectors that target specific cells in the inner ear.
Headquarters and Ownership
Akouos is headquartered at 645 Summer Street, Suite 200, Boston, MA 02210. The company is a wholly owned subsidiary of Eli Lilly and Company, one of the major players in the pharmaceutical industry. This strategic relationship supports Akouos's mission to advance its gene therapy programs from research through clinical development.